Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica

Friedemann Paul, Sven Jarius, Orhan Aktas, Martin Bluthner, Oliver Bauer, Heribert Appelhans, Diego Franciotta, Roberto Bergamaschi, Edward Littleton, Jacqueline Palace, Hans Peter Seelig, Reinhard Hohlfeld, Angela Vincent, Frauke Zipp

Research output: Contribution to journalArticle

Abstract

Background: Neuromyelitis optica (NMO) is a demyelinating disease of the central nervous system (CNS) of putative autoimmune aetiology. Early discrimination between multiple sclerosis (MS) and NMO is important, as optimum treatment for both diseases may differ considerably. Recently, using indirect immunofluorescence analysis, a new serum autoantibody (NMO-IgG) has been detected in NMO patients. The binding sites of this autoantibody were reported to colocalize with aquaporin 4 (AQP4) water channels. Thus we hypothesized that AQP4 antibodies in fact characterize NMO patients. Methods and Findings: Based on these observations we cloned human water channel AQP4, expressed the protein in a eukaryotic transcription/translation system, and employed the recombinant AQP4 to establish a new radioimmunoprecipitation assay (RIPA). Indeed, application of this RIPA showed that antibodies against AQP4 exist in the majority of patients with NMO (n = 37; 21 positive) as well as in patients with isolated longitudinally extensive transverse myelitis (n = 6; six positive), corresponding to a sensitivity of 62.8% and a specificity of 98.3%. By contrast, AQP4 antibodies were virtually absent in 291 other participants, which included patients with MS (n = 144; four positive), patients with other inflammatory and noninflammatory neurological diseases (n = 73; one positive), patients with systemic autoimmune diseases (n = 45; 0 positive), and healthy participants (n = 29; 0 positive). Conclusions: In the largest series reported so far to our knowledge, we quantified AQP4 antibodies in patients with NMO versus various other diseases, and showed that the aquaporin 4 water channel is a target antigen in a majority of patients with NMO. The newly developed assay represents a highly specific, observer-independent, and easily reproducible detection method facilitating clinically relevant discrimination between NMO, MS, and other inflammatory diseases.

Original languageEnglish
Pages (from-to)669-674
Number of pages6
JournalPLoS Medicine
Volume4
Issue number4
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Aquaporin 4
Neuromyelitis Optica
Antibodies
Aquaporins
Radioimmunoprecipitation Assay
Assays
Multiple Sclerosis
Autoantibodies
CNS Demyelinating Autoimmune Diseases
Transverse Myelitis
Neurology
Transcription
Indirect Fluorescent Antibody Technique
Autoimmune Diseases
Immunoglobulin G
Binding Sites
Healthy Volunteers
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Paul, F., Jarius, S., Aktas, O., Bluthner, M., Bauer, O., Appelhans, H., ... Zipp, F. (2007). Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Medicine, 4(4), 669-674. https://doi.org/10.1371/journal.pmed.0040133

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. / Paul, Friedemann; Jarius, Sven; Aktas, Orhan; Bluthner, Martin; Bauer, Oliver; Appelhans, Heribert; Franciotta, Diego; Bergamaschi, Roberto; Littleton, Edward; Palace, Jacqueline; Seelig, Hans Peter; Hohlfeld, Reinhard; Vincent, Angela; Zipp, Frauke.

In: PLoS Medicine, Vol. 4, No. 4, 04.2007, p. 669-674.

Research output: Contribution to journalArticle

Paul, F, Jarius, S, Aktas, O, Bluthner, M, Bauer, O, Appelhans, H, Franciotta, D, Bergamaschi, R, Littleton, E, Palace, J, Seelig, HP, Hohlfeld, R, Vincent, A & Zipp, F 2007, 'Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica', PLoS Medicine, vol. 4, no. 4, pp. 669-674. https://doi.org/10.1371/journal.pmed.0040133
Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Medicine. 2007 Apr;4(4):669-674. https://doi.org/10.1371/journal.pmed.0040133
Paul, Friedemann ; Jarius, Sven ; Aktas, Orhan ; Bluthner, Martin ; Bauer, Oliver ; Appelhans, Heribert ; Franciotta, Diego ; Bergamaschi, Roberto ; Littleton, Edward ; Palace, Jacqueline ; Seelig, Hans Peter ; Hohlfeld, Reinhard ; Vincent, Angela ; Zipp, Frauke. / Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. In: PLoS Medicine. 2007 ; Vol. 4, No. 4. pp. 669-674.
@article{729233b0f9504509b971270aaef578dd,
title = "Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica",
abstract = "Background: Neuromyelitis optica (NMO) is a demyelinating disease of the central nervous system (CNS) of putative autoimmune aetiology. Early discrimination between multiple sclerosis (MS) and NMO is important, as optimum treatment for both diseases may differ considerably. Recently, using indirect immunofluorescence analysis, a new serum autoantibody (NMO-IgG) has been detected in NMO patients. The binding sites of this autoantibody were reported to colocalize with aquaporin 4 (AQP4) water channels. Thus we hypothesized that AQP4 antibodies in fact characterize NMO patients. Methods and Findings: Based on these observations we cloned human water channel AQP4, expressed the protein in a eukaryotic transcription/translation system, and employed the recombinant AQP4 to establish a new radioimmunoprecipitation assay (RIPA). Indeed, application of this RIPA showed that antibodies against AQP4 exist in the majority of patients with NMO (n = 37; 21 positive) as well as in patients with isolated longitudinally extensive transverse myelitis (n = 6; six positive), corresponding to a sensitivity of 62.8{\%} and a specificity of 98.3{\%}. By contrast, AQP4 antibodies were virtually absent in 291 other participants, which included patients with MS (n = 144; four positive), patients with other inflammatory and noninflammatory neurological diseases (n = 73; one positive), patients with systemic autoimmune diseases (n = 45; 0 positive), and healthy participants (n = 29; 0 positive). Conclusions: In the largest series reported so far to our knowledge, we quantified AQP4 antibodies in patients with NMO versus various other diseases, and showed that the aquaporin 4 water channel is a target antigen in a majority of patients with NMO. The newly developed assay represents a highly specific, observer-independent, and easily reproducible detection method facilitating clinically relevant discrimination between NMO, MS, and other inflammatory diseases.",
author = "Friedemann Paul and Sven Jarius and Orhan Aktas and Martin Bluthner and Oliver Bauer and Heribert Appelhans and Diego Franciotta and Roberto Bergamaschi and Edward Littleton and Jacqueline Palace and Seelig, {Hans Peter} and Reinhard Hohlfeld and Angela Vincent and Frauke Zipp",
year = "2007",
month = "4",
doi = "10.1371/journal.pmed.0040133",
language = "English",
volume = "4",
pages = "669--674",
journal = "PLoS Medicine",
issn = "1549-1277",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica

AU - Paul, Friedemann

AU - Jarius, Sven

AU - Aktas, Orhan

AU - Bluthner, Martin

AU - Bauer, Oliver

AU - Appelhans, Heribert

AU - Franciotta, Diego

AU - Bergamaschi, Roberto

AU - Littleton, Edward

AU - Palace, Jacqueline

AU - Seelig, Hans Peter

AU - Hohlfeld, Reinhard

AU - Vincent, Angela

AU - Zipp, Frauke

PY - 2007/4

Y1 - 2007/4

N2 - Background: Neuromyelitis optica (NMO) is a demyelinating disease of the central nervous system (CNS) of putative autoimmune aetiology. Early discrimination between multiple sclerosis (MS) and NMO is important, as optimum treatment for both diseases may differ considerably. Recently, using indirect immunofluorescence analysis, a new serum autoantibody (NMO-IgG) has been detected in NMO patients. The binding sites of this autoantibody were reported to colocalize with aquaporin 4 (AQP4) water channels. Thus we hypothesized that AQP4 antibodies in fact characterize NMO patients. Methods and Findings: Based on these observations we cloned human water channel AQP4, expressed the protein in a eukaryotic transcription/translation system, and employed the recombinant AQP4 to establish a new radioimmunoprecipitation assay (RIPA). Indeed, application of this RIPA showed that antibodies against AQP4 exist in the majority of patients with NMO (n = 37; 21 positive) as well as in patients with isolated longitudinally extensive transverse myelitis (n = 6; six positive), corresponding to a sensitivity of 62.8% and a specificity of 98.3%. By contrast, AQP4 antibodies were virtually absent in 291 other participants, which included patients with MS (n = 144; four positive), patients with other inflammatory and noninflammatory neurological diseases (n = 73; one positive), patients with systemic autoimmune diseases (n = 45; 0 positive), and healthy participants (n = 29; 0 positive). Conclusions: In the largest series reported so far to our knowledge, we quantified AQP4 antibodies in patients with NMO versus various other diseases, and showed that the aquaporin 4 water channel is a target antigen in a majority of patients with NMO. The newly developed assay represents a highly specific, observer-independent, and easily reproducible detection method facilitating clinically relevant discrimination between NMO, MS, and other inflammatory diseases.

AB - Background: Neuromyelitis optica (NMO) is a demyelinating disease of the central nervous system (CNS) of putative autoimmune aetiology. Early discrimination between multiple sclerosis (MS) and NMO is important, as optimum treatment for both diseases may differ considerably. Recently, using indirect immunofluorescence analysis, a new serum autoantibody (NMO-IgG) has been detected in NMO patients. The binding sites of this autoantibody were reported to colocalize with aquaporin 4 (AQP4) water channels. Thus we hypothesized that AQP4 antibodies in fact characterize NMO patients. Methods and Findings: Based on these observations we cloned human water channel AQP4, expressed the protein in a eukaryotic transcription/translation system, and employed the recombinant AQP4 to establish a new radioimmunoprecipitation assay (RIPA). Indeed, application of this RIPA showed that antibodies against AQP4 exist in the majority of patients with NMO (n = 37; 21 positive) as well as in patients with isolated longitudinally extensive transverse myelitis (n = 6; six positive), corresponding to a sensitivity of 62.8% and a specificity of 98.3%. By contrast, AQP4 antibodies were virtually absent in 291 other participants, which included patients with MS (n = 144; four positive), patients with other inflammatory and noninflammatory neurological diseases (n = 73; one positive), patients with systemic autoimmune diseases (n = 45; 0 positive), and healthy participants (n = 29; 0 positive). Conclusions: In the largest series reported so far to our knowledge, we quantified AQP4 antibodies in patients with NMO versus various other diseases, and showed that the aquaporin 4 water channel is a target antigen in a majority of patients with NMO. The newly developed assay represents a highly specific, observer-independent, and easily reproducible detection method facilitating clinically relevant discrimination between NMO, MS, and other inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=34247534141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247534141&partnerID=8YFLogxK

U2 - 10.1371/journal.pmed.0040133

DO - 10.1371/journal.pmed.0040133

M3 - Article

C2 - 17439296

AN - SCOPUS:34247534141

VL - 4

SP - 669

EP - 674

JO - PLoS Medicine

JF - PLoS Medicine

SN - 1549-1277

IS - 4

ER -